Hormone therapy is one of the most effective treatments for managing hormone-receptor-positive breast cancer, a type that relies on estrogen or progesterone to grow. For many women, especially those in or after menopause, this approach can help prevent recurrence, slow progression, and improve survival outcomes. Unlike chemotherapy, which targets rapidly dividing cells, hormone therapy works more precisely by altering or blocking the body鈥檚 natural hormones that fuel cancer growth.
Nearly two-thirds of breast cancer cases are hormone-receptor-positive, meaning the tumour cells contain receptors that bind to estrogen or progesterone. When these hormones attach to the receptors, they stimulate cancer cells to multiply. Hormone therapy disrupts this process, depriving the cancer cells of the signals they need to thrive.
Doctors usually test a tumour sample after diagnosis to determine whether it is estrogen receptor (ER) or progesterone receptor (PR) positive. This step is crucial because hormone therapy is effective only for cancers that depend on these hormones for growth.
Hormone therapy works in two main ways:
Blocking hormone receptors: Medicines are used to stop estrogen from attaching to cancer cells, halting their growth.
wering hormone production: Some treatments reduce the amount of estrogen made by the ovaries or other tissues, cutting off the cancer鈥檚 supply of growth signals.
The treatment may be used before surgery (neoadjuvant therapy) to shrink tumours or after surgery (adjuvant therapy) to reduce recurrence risk. It can also be used in advanced cases to control disease spread and relieve symptoms.
The choice of medication depends on menopausal status, cancer stage, and individual tolerance.
These medicines, such as tamoxifen, bind to estrogen receptors and block estrogen from activating cancer cell growth. Tamoxifen is often used in both premenopausal and postmenopausal women and has shown significant success in reducing recurrence rates.
After menopause, the body continues to make small amounts of estrogen through an enzyme called aromatase, which converts androgens into estrogen. Aromatase inhibitors prevent this conversion. One of the most commonly prescribed options in this group is Arimidex 1mg, which contains the active component Anastrozole. This medicine is highly effective in lowering estrogen levels in postmenopausal women and is frequently recommended for five years following primary breast cancer treatment. By reducing estrogen production it helps prevent the growth of residual cancer cells and lowers the risk of recurrence.
In premenopausal women, shutting down ovarian function can be achieved using medications, radiation, or surgery. Medicines like goserelin temporarily block signals from the brain that trigger the ovaries to produce estrogen. In some cases, ovarian removal may be considered for long-term hormone suppression.
These medications, such as fulvestrant, not only block estrogen receptors but also promote their degradation, reducing the number of active receptors on cancer cells. They are often used when cancer becomes resistant to other hormone therapies.
Hormone therapy is usually prescribed for a long duration, often 5 to 10 years, to maintain continuous suppression of hormone activity. Research shows that extended therapy can further reduce recurrence in high-risk patients, though long-term treatment may increase certain side effects.
Because hormone therapy affects the body鈥檚 hormone balance, it can lead to a variety of side effects. These differ depending on the type of medication used and the patient鈥檚 menopausal status.
Common side effects include:
Hot flashes and night sweats
Joint or muscle pain
Vaginal dryness or discharge
Fatigue
Bone thinning in postmenopausal women
In rare cases, more serious issues like blood clots or cardiovascular complications may occur. Regular bone-density monitoring, calcium and vitamin D supplementation, and exercise can help mitigate bone-related effects.
After menopause, estrogen levels naturally decline, but small amounts are still produced by fat tissue and adrenal glands. This is why postmenopausal women can still benefit from hormone therapy. Medications like aromatase inhibitors specifically target these non-ovarian sources of estrogen, offering a more tailored approach for women beyond reproductive age.
Hormone therapy is often used alongside surgery, chemotherapy, and radiation for comprehensive cancer management. In advanced cases, it can also be combined with targeted therapies such as CDK4/6 inhibitors (palbociclib, ribociclib) or PI3K inhibitors, which enhance the effectiveness of hormone-blocking medicines.
Maintaining an active and healthy lifestyle can improve treatment tolerance and overall well-being. Incorporating physical activity, a balanced diet, and mindfulness practices can help manage fatigue and emotional distress associated with treatment.
A diet rich in vegetables, fruits, lean proteins, and whole grains supports hormonal balance and bone health. Avoiding alcohol and quitting smoking can further reduce recurrence risk.
Routine follow-ups are essential to monitor progress, assess side effects, and adjust medication if needed. Regular mammograms, blood tests, and bone density scans help healthcare providers ensure the therapy is working effectively without compromising other aspects of health.
Patients are also encouraged to promptly discuss any new symptoms with their oncologist, as these may signal treatment-related changes or the need for additional interventions.
Living with breast cancer can be emotionally challenging, particularly during long-term treatments like hormone therapy. Many women experience anxiety, fear of recurrence, or changes in self-image due to menopause-related symptoms. Counselling, peer support groups, and open communication with loved ones can help build resilience and emotional stability during recovery.
Hormone therapy remains a cornerstone in managing hormone-sensitive breast cancer. By targeting hormonal pathways that fuel tumour growth, it provides a personalised, less invasive, and highly effective approach, particularly for postmenopausal women. With advances in treatment options, continuous medical supervision, and a strong support system, patients can look forward to improved outcomes and a better quality of life beyond diagnosis.
